Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Effectiveness of Crosslinked HA on the Adhesion Preventing After Trigger Finger Release Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Agree to participate in this study and sign informed consent form~2. Age 20 to 65 years of male or female~3. The trigger finger, except thumb, classified as 3 to 4 points and plan to conduct trigger finger release surgery;~4. The trigger finger, except thumb, classified as 2 points with the symptom of flexion contracture and plan to conduct trigger finger release surgery;~5. Agree to comply with the follow-up schedule of this study~Exclusion Criteria:~1. Target finger has other adhesion in tendon, joint, or proximal nerve, neuropathy, compression injury or other disease;~2. Other fingers in the same hand as the target finger have other adhesion in tendon, joint, or proximal nerve, neuropathy, or compression injury;~3. Contralateral finger has other adhesion in tendon, joint, or proximal nerve, neuropathy, or compression injury;~4. The operation site was conducted tendon transplantation or any surgery in past 6 months;~5. Receiving orthopedic-related treatment which may affect the evaluation of the study;~6. The skin of the operation site with infection, deficiency, or needing skin transplantation;~7. With poorly controlled chronic diseases, such as diabetes mellitus;~8. Patient with autoimmune disease (such as rheumatoid arthritis), malignant tumors, coagulation diseases, heart diseases, mental diseases, etc., may cause patients to participate in the trial at higher risk;~9. Patient who has taken cortisol within the past 6 months, systemic corticosteroids within the past 2 months, immunosuppressive drugs within past 3 months, or non-steroidal anti-inflammatory drugs (NSAIDs) everyday within 1 week or NSAIDs within 8 hours occasionally. (subjects who have received inhaled/intranasal corticosteroids could be considered to include.);~10. With clinical meaningful coagulation disorders, underdoing anticoagulant treatment or taking blood circulation promotion and blood stasis removement medications within the past 10 days;~11. With history of hypersensitivity or allergy to hyaluronic acid or any component of the device; With history of hypersensitivity or allergy to Gram-positive bacteria or Streptococcus proteins; other severe hypersensitivity history unsuitable for participating in the study;~12. Pregnant, planning pregnancy or in breastfeeding females;~13. Other circumstances which judged to be unsuitable for participating in the study by the investigator.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Hyaluronic acid (HA) (Type: EXPERIMENTAL): Hyaluronic acid (HA)
- Saline (Type: PLACEBO_COMPARATOR): Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).